Benign fibrous histiocytoma is a mesenchymal tumor that usually has benign fibrous histiocytoma treatment a benign behavior and rarely leads to metastasis. The tumor is usually asymptomatic or may cause localized pain benign fibrous histiocytoma treatment and swallowing. Most cases have a favorable prognosis, but certain types have a tendency for recurrence or metastasis benign fibrous histiocytoma treatment in the lungs, lymph nodes, soft tissues or liver [ 1, 2].
The tumor is rare and commonly affects adults between the benign fibrous histiocytoma treatment ages of 20 and 50 years old. The differential diagnose should be performed with non-ossifying fibroma, dermatofibrosarcoma protuberans, leiomyosarcoma, melanocytic or vascular tumors, angiomatoid malignant fibrous histiocytoma, Spitz nevus, xanthoma or atrophic fibrous histiocytoma [ 3, 4]. 2. Material and Methods
Data was collected from clinical records, operative protocol and pathology reports of the patient. Parents signed an informed consent that allows the usage of benign fibrous histiocytoma treatment patient’s data for research and teaching purposes. The references were selected after performing a literature review conducted benign fibrous histiocytoma treatment in Medline using the keywords “benign fibrous histiocytoma” combined with “children”. 3. Case Report
Physical examination: 4 years old male patient with a normal weight and benign fibrous histiocytoma treatment height for his age, in no apparent distress, with no fever (temperature 98,3 degrees), with normally colored skin and mucosa; extremities were warm, with no cyanosis or clubbing; normal auscultation of the lungs, and normal respiratory rate- 12/min; no pathological heart sounds or murmurs, blood pressure 99/68 mm Hg with no orthostatic changes; the abdomen was soft and non-tender, the liver, spleen and kidneys had normal size. Urine and stool were normal. No neurologic focal deficit was present, cranial nerves were normal, no balance deficits were noticed. The tumor was mobile, not fixed to the underlying vertebra, covered by normal skin. Laboratory data only showed mild iron deficiency (7 μmol/L, with a normal value of 13-31μmol/L).
Regarding tumor genetics, few data exists. Clonal chromosomal abnormalities have been reported in 38% of cases. Data is also scarce regarding disease etiology, but it has been observed that it is sometimes associated benign fibrous histiocytoma treatment with insect bites, vaccines or trauma. [ 5] Differentiation line is unclear and multiple tumors may be associated benign fibrous histiocytoma treatment with immunosuppression.
Generally, the tumor is well defined, but has no capsule. The stroma is composed of collagen and seldom has a benign fibrous histiocytoma treatment myxoid component. Spindle cells have scant cytoplasm and the nuclei are ellongated. The tumor may also comprise foamy histiocytes, multinucleated giant cells, chronic inflammatory cells and branching vessels. Cells are surrounded by collagen bundles.
The immunohistochemical profile is highly variable. The tumor may test positive for vimentin, CD 34, tenascin, calponin, actin, desmin, myosin. Histological differential diagnose should be made with atypical fibroxanthoma (the storiform pattern is less defined, the pleomorphism is marked), with dermatofibrosarcoma protuberans (tests positive for CD 34), Kaposi sarcoma (immunosuppression context, lacks fibrohistiocytic cells), leiomyoma (benign muscular tumor with characteristic morphology).
Tumors, despite their benign character, may have an aggressive growth pattern. Recurrence rate is between 5 and 25%. Aneurysmal and atypical variants are more likely to metastasize. The suspicion of metastatic potential is mainly clinical. In case the patient presents with these variants, array-based comparative genomic hybridization should be performed, that might show abnormalities of chromosome 7, 8q and Xq. Recurrence rate depends on the lipid content, greater lipid component leads to a smaller recurrence rate. The tumor rarely leads to metastases and rarely regresses by benign fibrous histiocytoma treatment itself. [ 7]
Orbital localization of benign histiocytoma leads to more severe symptoms, such as proptosis, dry eye or blurry vision, as one study showed. [ 10] Orbital histiocytoma is benign in 60% of cases. In this case, the tumor most often appears in patients who have previously benign fibrous histiocytoma treatment received orbital irradiation for retinoblastoma. Differential diagnose of orbital histiocytoma should include schwanoma, cavernous hemangioma, rhabdomyosarcoma or hemangiopericytoma. [ 11] The tumor rarely extends into the skull.
Orbital tumor should be excised entirely, since incomplete excision may lead to recurrence. Chemotherapy or radiotherapy have so far been limited in this benign fibrous histiocytoma treatment type of tumor, but the ten-year survival of patients with benign, locally aggressive, and malignant fibrous histiocytoma was 100 per cent, 92 per cent, and 23 per cent, respectively. [ 10] Furthermore, surgery is not without its risks, such as infection, blindness, incomplete excision, retrobulbar hemorrhage. The same study [ 10] shows a rate of recurrence was 31 per cent for benign fibrous histiocytoma treatment the benign tumors, 57 per cent for the locally aggressive tumors, and 64 per cent for the malignant tumors.
Regarding tumor location, presentation may also vary. Another study [ 12] states that 58% of lesions appear on the extremities, 22% on the head and neck, 11% on the trunk and 9% in the deep soft tissue of the retroperitoneum, mediastinum, or pelvis (9%). The same authors describe the presence of giant multinucleate cells benign fibrous histiocytoma treatment in 59% of cases; other common findings included a hemangiopericytoma-like vascular pattern (42%) and stromal hyalinization (39%). Other distinctive histologic features identified in other studies were a benign fibrous histiocytoma treatment fascicular growth pattern, predominance of eosinophilic spindle cells with tapering nuclei and a benign fibrous histiocytoma treatment moderate mitotic rate (mean three per 10 high-power fields). [ 4] None of those aspects were met in our patient.
In our patient, the tumor was removed in an early stage of evolution, as soon as it was discovered on clinical examination. Once distance metastases appear, prognosis may not be as favorable; unfavorable prognosis also characterizes the malignant variant of the disease, since tumor sensitivity to chemotherapy and radiotherapy is poor and benign fibrous histiocytoma treatment rescue following initially failed treatment is difficult. Authors believe that clinical trials should also address this pathology, in order to better characterize its postoperative evolution and particularities. 5. Conclusion
Although it may be asymptomatic, especially if only subcutaneous tissue is involved, benign fibrous histiocytoma has potential for fast evolution, metastasis and re-apparition and should be excised in all cases. If evolution is unfavorable, cryotherapy should be applied in order to reduce recurrence. Case particularity consists in the young age of this patient, given the fact that this type of tumor usually affects benign fibrous histiocytoma treatment patients over 20 years of age. References 
At Adamas Pharmaceuticals, Inc., we seek to redefine the treatment experience for patients suffering benign fibrous histiocytoma treatment from chronic…
The iRestore Laser Hair growth system is a red light cellular benign fibrous histiocytoma therapy device that has been tested and verified to promote…
In 2016, the Department of Statistics Malaysia reported that the country’s birth rate was plummeting, reaching a new historic low. The country’s total…